The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.

Cabaletta Bio reports durable Phase 1/2 results for rese-cel in autoimmune diseases

Nov 8, 2026 15:00 (12h ago)

Verifying

Cabaletta Bio announced Phase 1/2 clinical data for rese-cel.
Rese-cel showed durable benefits without immunomodulators across three autoimmune diseases.
The data covered dermatomyositis, lupus nephritis and systemic sclerosis patients.